Leadership Team
Dr Julian Chick
CEO & Managing Director
…Dr Julian Chick is an experienced healthcare executive with over 20 years’ experience in senior management, including at ASX-listed Avexa and Admedus. He has held roles as Chief Executive Officer, COO and Head of Business Development, leading R&D projects and launching medical devices into global markets.
He has developed and obtained FDA USA clearance for four tissue-based medical devices, has eight years’ investment banking experience and holds a PhD in Muscle Physiology.
Dr David Rhodes
CSO & Director
…Dr David Rhodes has more than 20 years’ experience in the healthcare and biotechnology industries, holding numerous senior management roles and developing technologies through to market approval, including obtaining FDA USA and European marketing authorisation approvals for medical devices. He has held senior roles at ASX-listed Amrad, Admedus, AdAlta and Avexa.
Dr Rhodes has published in peer-reviewed journals, is an inventor on numerous patents and holds a PhD in Biochemistry.
Maja McGuire
Independent Chair
…Ms McGuire is an experienced corporate executive and company director with ASX-listed company experience as a non-executive director, general counsel and senior executive. She brings expertise in governance, corporate strategy and regulatory oversight, supporting the commercialisation of innovative technologies.
She has held executive roles with Anteris Technologies Ltd (ASX: AVR) and Alexium International Group Ltd (ASX: AJC), holds law and business qualifications from The University of Western Australia, and serves on multiple ASX-listed company boards.
Dr Paul Savage
Independent Non-executive Director
…Dr Paul Savage recently retired from a 35-year career at CSIRO, including 20 years as Research Director of the Biomedical Manufacturing Program, leading 150 scientists and engineers and structuring commercial and collaborative research deals across biotech and multinational organisations.
He later served as Science Director of CSIRO Manufacturing, holds a PhD in Chemistry and an MBA in Technology Management, and has published extensively while serving on multiple biotechnology and government advisory boards.
Dr Alex Adamides MD FRACS
Chief Medical Officer
(CMO)
…Dr Alex Adamides studied medicine at the University of Nottingham and completed surgical training in Edinburgh and Australia. He became a Fellow of the Royal Australasian College of Surgeons in 2012 and is a consultant neurosurgeon at the Royal Melbourne Hospital.
He is an honorary clinical senior lecturer at Melbourne University, a reviewer for the Journal of Clinical Neuroscience, and has developed pre-clinical models testing the safety and efficacy of surgical implants for peripheral nerve and dura repair.
Scientific Advisory Board
Dr Alex Adamides MD FRACS
Chief Medical Officer (CMO)
Dr Alex Adamides studied medicine at the University of Nottingham and completed…surgical training in Edinburgh and Australia. He became a Fellow of the Royal Australasian College of Surgeons in 2012 and is a consultant neurosurgeon at the Royal Melbourne Hospital.
He is an honorary clinical senior lecturer at Melbourne University, a reviewer for the Journal of Clinical Neuroscience, and has developed pre-clinical models testing the safety and efficacy of surgical implants for peripheral nerve and dura repair.
Dr. Michael Findlay MBBS, PhD, FRACS, FACS
Dr Michael Findlay is a Plastic, Reconstructive and Hand Surgeon with expertise in…microsurgery, stem cells, tissue engineering and biomaterials research. He studied Medicine, Surgery and Science at the University of Queensland before completing advanced training in Plastic, Reconstructive and Hand Surgery. He spent three years as a Microsurgery Fellow at St Vincent’s Hospital Melbourne, where he completed a PhD in tissue-engineered breast reconstruction. He later undertook a fellowship at New York University’s Institute of Reconstructive Plastic Surgery.
Dr Findlay became a Fellow of the Royal Australasian College of Surgeons in 2008 and the American College of Surgeons in 2013. His research led to a patent and the creation of NeoPec, a start-up focused on tissue-engineered breast reconstruction. In 2012, he received the Fulbright Scholarship for Victoria and became Stanford University’s inaugural Applied Regenerative Medicine Fellow, contributing to stem cell trials and biomaterials research.
He returned to Australia in 2016 and currently works at Peter MacCallum Cancer Centre and Canberra Hospital, undertaking complex cancer and trauma reconstruction. He continues translational research focused on tissue regeneration, tissue engineering and emerging surgical technologies.